Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jazz Pharmaceuticals plc

http://jazzpharma.com

Latest From Jazz Pharmaceuticals plc

BIO 2022 Notebook: How Is Industry Faring In Turbulent Times?

News and views from day one of the BIO annual meeting include reflections on how the biopharma industry is adjusting to current conditions. EY's annual Beyond Borders reports predicts continued success based on past performance, CBRE tracks how the life science industry is spreading out, and Organon's CEO discusses the company's biosimilars deal with Henlius.

Business Strategies Financing

BIO 2022 Notebook: How Is Industry Faring In Turbulent Times?

News and views from day one of the BIO annual meeting include reflections on how the biopharma industry is adjusting to current conditions. EY's annual Beyond Borders reports predicts continued success based on past performance, CBRE tracks how the life science industry is spreading out, and Organon's CEO discusses the company's biosimilars deal with Henlius.

Business Strategies Financing

Can China Innovate? Degron Aims For First-In-Class TPD Therapies

Fresh out of an impressive new round of financing and armed with $32m, Shanghai's Degron Therapeutics is aiming for nothing but first-in-class treatments. Its co-founder and CSO shares views on creating original innovative drugs from inside China in an exclusive interview with Scrip.

China Research & Development

Krka Keeps Focus On Russia-Ukraine As Sales Climb 9%

Slovenia’s Krka surprised the market with nearly 10% group turnover growth in the first quarter, driven by increases in all six of its sales regions, “most key markets, and by all product and service groups.”

Sales & Earnings Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Contract Manufacturing Organization
  • Biotechnology
    • Drug Discovery Tools
  • Other Names / Subsidiaries
    • Alizé Pharma II
    • Azur Pharma Public Limited Company
    • Cavion, Inc.
    • Cavion LLC (Tau Therapeutics LLC
    • Xdynia LLC)
    • Celator Pharmaceuticals, Inc.
    • Gentium S.p.A.
    • GW Pharmaceuticals plc
    • Jazz Pharmaceuticals Ireland Limited
    • Orphan Medical, Inc.
UsernamePublicRestriction

Register